IDXX Idexx Laboratories

Q2 2025 10-Q

Filed: Aug 4, 2025Period ending Jun 30, 2025

Health Care

In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR

Idexx Laboratories (IDXX) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 4, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Management Discussion & Analysis

• No revenue or profitability figures disclosed in provided excerpt
• No segment or product line performance data presented

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.1B

Net Income

$294M

Gross Margin

62.6%

Operating Margin

33.6%

Net Margin

26.5%

Source: XBRL data from Idexx Laboratories Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Idexx Laboratories Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Idexx Laboratories

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.